Shanghai RAAS Blood Products Co Ltd Class A (002252) — Financial Flexibility Index
Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Financial Flexibility Index of -0.13x as of December 2025. Free cash flow of CN¥-672.37 Million (operating CF CN¥-843.75 Million minus capex CN¥171.38 Million) represents 0% of total liabilities (CN¥5.33 Billion). Also explore 002252 net asset momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shanghai RAAS Blood Products Co Ltd Class A Financial Flexibility Index (2005–2025)
Historical Financial Flexibility Index trend for Shanghai RAAS Blood Products Co Ltd Class A across 21 annual periods. Check 002252 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
Year-by-year free cash flow to debt coverage for Shanghai RAAS Blood Products Co Ltd Class A. For the full company profile including market capitalisation, see Shanghai RAAS Blood Products Co Ltd Clas market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.05x | CN¥274.12 Million | CN¥-104.89 Million | CN¥5.34 Billion | ▲ +215.9% |
| 2024 | -0.04x | CN¥-74.91 Million | CN¥-482.06 Million | CN¥1.69 Billion | ▼ -103.7% |
| 2023 | 1.20x | CN¥2.73 Billion | CN¥2.28 Billion | CN¥2.28 Billion | ▲ +0.9% |
| 2022 | 1.19x | CN¥1.95 Billion | CN¥1.73 Billion | CN¥1.64 Billion | ▲ +5.5% |
| 2021 | 1.12x | CN¥1.50 Billion | CN¥1.29 Billion | CN¥1.33 Billion | ▼ -71.2% |
| 2020 | 3.91x | CN¥1.42 Billion | CN¥1.17 Billion | CN¥363.74 Million | ▲ +37.6% |
| 2019 | 2.84x | CN¥1.03 Billion | CN¥872.69 Million | CN¥361.95 Million | ▲ +236.1% |
| 2018 | 0.84x | CN¥419.44 Million | CN¥262.50 Million | CN¥496.56 Million | ▲ +291.1% |
| 2017 | 0.22x | CN¥426.60 Million | CN¥268.76 Million | CN¥1.98 Billion | ▼ -58.9% |
| 2016 | 0.53x | CN¥785.71 Million | CN¥638.22 Million | CN¥1.50 Billion | ▼ -51.2% |
| 2015 | 1.08x | CN¥907.81 Million | CN¥762.42 Million | CN¥843.64 Million | ▲ +53.0% |
| 2014 | 0.70x | CN¥531.02 Million | CN¥465.96 Million | CN¥755.16 Million | ▲ +741.2% |
| 2013 | 0.08x | CN¥39.57 Million | CN¥-90.11 Million | CN¥473.37 Million | ▼ -96.2% |
| 2012 | 2.19x | CN¥413.16 Million | CN¥263.46 Million | CN¥188.79 Million | ▼ -49.3% |
| 2011 | 4.31x | CN¥354.82 Million | CN¥178.03 Million | CN¥82.26 Million | ▲ +47.7% |
| 2010 | 2.92x | CN¥289.42 Million | CN¥200.21 Million | CN¥99.12 Million | ▲ +2.1% |
| 2009 | 2.86x | CN¥177.01 Million | CN¥116.01 Million | CN¥61.88 Million | ▲ +59.7% |
| 2008 | 1.79x | CN¥136.87 Million | CN¥107.64 Million | CN¥76.42 Million | ▲ +22.2% |
| 2007 | 1.47x | CN¥200.17 Million | CN¥175.71 Million | CN¥136.53 Million | ▲ +276.0% |
| 2006 | 0.39x | CN¥65.67 Million | CN¥53.58 Million | CN¥168.39 Million | ▼ -47.5% |
| 2005 | 0.74x | CN¥75.71 Million | CN¥54.02 Million | CN¥101.93 Million | — |